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Introduction: The cell of origin for estrogen receptor α–positive (ERα+) breast cancer is probably a luminal stem
cell in the terminal duct lobular units. To model these cells, we have used the murine myoepithelial layer in the
mouse mammary ducts as a scaffold upon which to build a human luminal layer. To prevent squamous metaplasia,
a common artifact in genetically-engineered breast cancer models, we sought to limit activation of the epidermal
growth factor receptor (EGFR) during in vitro cell culture before grafting the cells.
Methods: Human reduction mammoplasty cells were grown in vitro in WIT medium. Epidermal growth factor
in the medium was replaced with amphiregulin and neuregulin to decrease activation of EGFR and increase
activation of EGFR homologs 3 and 4 (ERBB3 and ERBB4). Lentiviral vectors were used to express oncogenic
transgenes and fluorescent proteins. Human mammary epithelial cells were mixed with irradiated mouse
fibroblasts and Matrigel, then injected through the nipple into the mammary ducts of immunodeficient mice.
Engrafted cells were visualized by stereomicroscopy for fluorescent proteins and characterized by histology and
immunohistochemistry.
Results: Growth of normal mammary epithelial cells in conditions favoring ERBB3/4 signaling prevented squamous
metaplasia in vitro. Normal human cells were quickly lost after intraductal injection, but cells infected with lentiviruses
expressing CCND1, MYC, TERT, BMI1 and a short-hairpin RNA targeting TP53 were able to engraft and progressively
replace the luminal layer in the mouse mammary ducts, resulting in the formation of an extensive network of
humanized ducts. Despite expressing multiple oncogenes, the human cells formed a morphologically normal
luminal layer. Expression of a single additional oncogene, PIK3CA-H1047R, converted the cells into invasive
cancer cells. The resulting tumors were ERα+, Ki67+ luminal B adenocarcinomas that were resistant to treatment
with fulvestrant.
Conclusions: Injection of preneoplastic human mammary epithelial cells into the mammary ducts of immunodeficient
mice leads to replacement of the murine luminal layer with morphologically normal human cells. Genetic manipulation
of the injected cells makes it possible to study defined steps in the transformation of human mammary epithelial cells in
a more physiological environment than has hitherto been possible.* Correspondence: r.iggo@bordeaux.unicancer.fr
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Pioneering studies by the Weinberg group have shown
that normal human cells can be fully converted into
tumor cells by targeting a small number of processes
known to be abnormal in cancer, including telomere
maintenance, the restriction point, cell cycle checkpoints
and apoptosis [1]. Human mammary epithelial cells
transformed in this way have been widely used, but they
frequently form tumors with histological features rarely
seen in human breast cancer, in particular squamous cell
carcinoma [2]. This is probably caused by excessive acti-
vation of the epidermal growth factor receptor (EGFR)
[3]. Because squamous metaplasia increases with time
in culture, current approaches attempt to shorten the
transformation process as much as possible, often to as
little as 24 hours [4,5]. Squamous cell changes are also
commonly seen in transgenic mouse models of breast
cancer, where part of the explanation may lie in mistar-
geting of oncogenes to myoepithelial or bipotent pro-
genitor/stem cells rather than luminal stem cells [6].
About 70% of human breast cancers express the estro-
gen receptor α (ERα, ESR1), but genetically defined tu-
mors based on transformation of normal human cells
are usually ERα-negative (ER−). Because the ESR1 gene
is rarely amplified in breast cancer, ERα expression is
normally ascribed to a lineage choice that traps the cells
in an ERα+ state. The most likely cell of origin for this
event is a luminal progenitor or stem cell located in the
terminal duct lobular unit (TDLU) [7].
Traditional breast cancer models based on injection of
tumor cells directly into the mammary fat pad [8] or
under the renal capsule [9] do not take into account the
unique features of the microenvironment in which
breast cancers develop. Behbod and colleagues recently
described an intraductal injection technique that dissemi-
nates tumor cells throughout the mouse mammary ductal
tree, including the TDLUs [10]. This approach places
potential tumor cells at or near the normal point of origin
of breast cancer and faithfully reproduces the histology of
human ductal carcinoma in situ (DCIS) [11].
In this article, we describe an approach based on the
Behbod intraductal injection technique using genetically
engineered cells cultured in conditions favoring EGFR
homolog 3 (ERBB3) signaling. Cells transduced with vectors
expressing CCND1, MYC, TERT, BMI1 and a short-hairpin
RNA targeting p53 (TP53) were able to form a morpho-
logically normal luminal layer. Introduction of a single
additional activated oncogene, PIK3CA-H1047R, converted
them into ERα+ invasive ductal adenocarcinomas.
Methods
Lentiviral vectors
The lentiviral plasmid vector expressing TERT and puro-
mycin acetyltransferase (pac) (pSD-83) was described byDuss et al. [12]. The vector expressing BMI1 and cyan
fluorescent protein (CFP) (pER7) was constructed from
pSD-84 [12] by replacing the pac gene with CFP
by standard cloning. The vector expressing MYC and
hygromycin phosphohydrolase (hph) (pSV32) was con-
structed by shuffling the MYC open reading frame from
pSD-94 [12] into pLenti PGK Hygro DEST (Addgene
plasmid 19066; Addgene, Cambridge, MA, USA) by
Gateway cloning. The vector expressing CCND1 and
neomycin phosphotransferase (npt) (pSV31) was con-
structed by Gateway cloning of the CCND1 open reading
frame from pENTR-CCND1 (PlasmID HsCD00001252)
into pLenti PGK Neo DEST (Addgene plasmid 19067).
The pLVTH-sip53 vector expressing green fluorescent pro-
tein (GFP) and a short-hairpin RNA targeting TP53 was
obtained from Addgene (plasmid 12239). The vector ex-
pressing PIK3CA-H1047R and hph (pER157) was con-
structed by cloning the PIK3CA-H1047R open reading
frame from pBABE-PIK3CA (PlasmID clone 25920) into
pENTR1A to give pER152, then transferred by Gateway
cloning into pLenti CMV/TO Hygro DEST (Addgene
plasmid 17484). The vector expressing tdTomato (pER5)
was kindly provided by Francois Moreau-Gaudry.
Western blot analysis
Cells were collected 4 to 7 days posttransfection and
lysed in SDS-PAGE sample buffer [13]. Cell lysates were
separated by SDS-PAGE and transferred onto nitrocellu-
lose membranes. The membranes were blocked with 5%
fat-free milk powder in 150 mM NaCl, 50 mM Tris-HCl,
pH 8.0, 0.1% Tween 20 (TBST) and incubated overnight
at 4°C with the following antibodies: telomerase catalytic
subunit (TERT) (Y182), phosphatidylinositol 3-kinase
(PI3K) p110α (04-399), ΔN-p63 (p40 [5-17] PC373),
GATA binding protein 3 transcription factor (GATA3)
(09-076) (EMD Millipore, Billerica, MA, USA); B lymph-
oma Moloney murine leukemia virus insertion region 1
(BMI1) (D20B7), keratin 18 (DC10), cyclin D1 (DCS6),
myc (D84C12), Akt (9272), phospho-Akt-T308 (4056/
244 F9), ERBB3 (4754) (Cell Signaling Technology,
Danvers, MA, USA); Forkhead box A1 transcription
factor (FOXA1) (Ab55-178; Abcam, Cambridge, UK);
AGR2 (1C3), tubulin (B-5-1-2) (Sigma-Aldrich, St Louis,
MO, USA); keratin 14 (LL002, gift from Birgit Lane);
ERα (Ab-16, RB-1493) (Thermo Scientific, Waltham,
MA, USA) and p53 (D01, gift from David Lane).
After three washes in TBST, bound primary anti-
bodies were detected by incubation with horseradish
peroxidase (HRP)–conjugated anti-rabbit, anti-mouse
or anti-goat immunoglobulin G (IgG) (GE Healthcare
Life Sciences, Pittsburgh, PA, USA) at room temperature
for 1 hour, washed again in TBST and visualized using
enhanced chemiluminescence reagents (GE Healthcare
Life Sciences). Images were captured with a Fusion FX7
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Hyperfilm ECL (GE Healthcare Life Sciences).
Flow cytometry analysis
Cells were grown in WIT medium (mammary culture
medium developed by Tan Ince [2]), detached using
0.5% trypsin-ethylenediaminetetraacetic acid (Invitrogen,
Carlsbad, CA, USA), pelleted, washed and counted. A
total of 105 cells were incubated for 20 minutes with the
following antibodies: allophycocyanin (APC)-conjugated
anti-epithelial cell adhesion molecule (EPCAM), phyco-
erythrin (PE)-conjugated anti-CD49f and PE-conjugated
anti-CD10 (BD Biosciences, San Jose, CA, USA). Non-
specific PE-IgG2a and APC-IgG1 (BD Biosciences) were
used as control antibodies. The gates marking the quad-
rants in the figures were set to exclude cells labeled by
the control antibodies. Cells were washed three times,
then analyzed on a FACSCalibur flow cytometer (BD
Biosciences) using CellQuest Pro software.
Immunofluorescence and immunohistochemistry
Paraffin-embedded mammary tissues were sectioned at
4 μm, deparaffinized and boiled in pH 6.0 citrate buffer
to retrieve antigens. For immunofluorescence, sec-
tions were blocked in Dako REAL Peroxidase-Blocking
Solution S2023 for 10 minutes and incubated with pri-
mary antibodies specific for p63 (4A4, 1:40 dilution;
Dako, Carpinteria, CA, USA) and GFP (ab290, 1:800
dilution; Abcam) for 30 minutes. Donkey anti-rabbit
IgG conjugated to Alexa Fluor 488 (1:400 dilution;
Invitrogen) was used to detect the anti-GFP antibody.
An M.O.M. ImmPRESS HRP (Peroxidase) Polymer Kit
(MP-2400; Vector Laboratories, Burlingame, CA, USA)
and cyanine 3–conjugated goat anti-HRP (123-165-021,
1:200 dilution; Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) were used according to the manu-
facturers’ instructions to detect the anti-p63 antibody.
Sections omitting the primary antibody were used as
negative controls. Nuclei were visualized with 4′,6-
diamidino-2-phenylindole, and sections were mounted
with Fluoromount mounting medium (Sigma-Aldrich).
Slides were scanned on a Leica spinning disk DM6000
B confocal microscope (Leica Microsystems, Wetzlar,
Germany). Immunohistochemical staining was performed
on a BenchMark ULTRA instrument (Ventana Medical
Systems, Tucson, AZ, USA) according to the manufac-
turer’s protocol with the following antibodies: ERα (SP1,
32 minutes, prediluted; Ventana Medical Systems), pro-
gesterone receptor (1E2, 12 minutes, prediluted; Ventana
Medical Systems), p53 (DO7, 32 minutes, 1:50 dilution;
Dako), keratin 5/6 (D5/16B4, 32 minutes, 1:50 dilution;
Dako), keratin 14 (LL002, 40 minutes + amplification,
prediluted; Ventana Medical Systems), keratin 8/18 (5D3,
20 minutes, 1:200 dilution; Novocastra/Leica Microsystems,Milton Keynes, UK), keratin 19 (A53-b/A2.26, 32 minutes,
prediluted; Ventana Medical Systems), keratin 7 (SP52,
32 minutes, prediluted; Ventana Medical Systems), smooth
muscle actin (SMA) (1A4, 32 minutes, 1:12,000 dilution;
Sigma-Aldrich), p63 (4A4, 32 minutes, 1:100 dilution;
Dako), Ki67 (30-9, 32 minutes, prediluted; Ventana Medical
Systems) and GFP (number sc-9996, B-2, 32 minutes,
1:400 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA, USA).
Bioinformatics
To identify the normal cell types expressing EGFR family
members in human reduction mammoplasty tissue, the
most variable probes for each EGFR family member
were selected from the Lim et al. Gene Expression
Omnibus [GEO:GSE16997] series matrix file [14]. The
error bars in Figure 2A are standard errors of the mean.
The P-values shown are derived from t-tests performed
to compare the mature luminal with the indicated popu-
lations. The tumor analysis in Figure 2B and 2C was
performed on [GEO:GSE6861] Affymetrix GeneChip
Human X3P Array (Affymetrix, Santa Clara, CA, USA)
gene expression data derived from large operable or lo-
cally advanced breast cancer [15,16]. The .CEL files were
normalized with robust multiarray average (RMA) in R
[17], filtered to remove probe sets spanning a region <56
base pairs, and the most variable probe sets for EGFR
family members were selected based on the standard de-
viation across all the tumors. The classification shown in
Figure 2B and 2C into luminal, molecular apocrine and
basal-like tumors is based on expression of FOXA1
(positive in luminal and molecular apocrine tumors) and
ESR1 (positive in luminal tumors). Both genes show
strongly bimodal expression; the cutoff is the nadir be-
tween the two peaks of the bimodal distributions. This
classification splits breast tumors into the three groups
described by Farmer et al. [18]. FOXA1 was used instead
of AR because the X3P probes work slightly better (both
genes are excellent markers for luminal and molecular
apocrine tumors). The plot in Figure 2B shows the raw
expression values generated by RMA. These values were
converted to a distribution with the density command in
R using the default parameters, then the maximum of
each distribution was scaled to 1 to make it easier to
compare the distributions in Figure 2C.
Cell biology
Reduction mammoplasty samples were donated by
healthy premenopausal women between the ages of 21
and 40 with no previous history of breast cancer. The
study was approved by the Tayside Tissue Bank Ethics
Committee (project TR000015), and patients gave us
their written informed consent to participate. Breast pri-
mary epithelial cells (BPECs) were prepared by using
Figure 1 Transformed BPECs grown in pWIT medium form
squamous tumors. Human mammary epithelial cells were infected
with vectors expressing TERT, BMI1, MYC and ESR1 (3G-ER cells).
(A) Western blot showing expression of the transgenes in
non-transduced parental cells (NT) and transformed cells (3G-ER)
(B and C) Tumor formation two weeks after subcutaneous injection
of 3G-ER cells into NSG mice (n=2). (B) Stereomicrograph showing
tdTomato fluorescence from the tumor. Scale bar = 1 mm. (C)
Glandular regions express keratin 8/18 (K8/18); squamous regions
express keratin 14 (K14). All of the cells are estrogen receptor
α–positive (ERα+), because one of the lentiviruses used to transform
the cells expresses ESR1. H&E, Hematoxylin and eosin. Scale bars: upper
panels = 500 μm; lower panels = 200 μm. At 3 weeks (D) (n= 2) and
5 weeks (E) (n= 5) after injection, the tumors are dominated by stratified
cells undergoing terminal squamous differentiation, leading to the
formation of keratin pearls. Keratin pearls are marked by asterisks.
Scale bars = 200 μm.
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5% O2 incubator in Primaria dishes (BD Biosciences) in
WIT medium containing 10 ng/ml basic fibroblast
growth factor and either 10 ng/ml epidermal growth fac-
tor (EGF) for pWIT or 5 ng/ml NRG1 and 10 ng/ml
AREG for svWIT [2]. Low-passage cultures of BPECs
were sequentially infected with lentiviruses and selected
for 4 to 10 days in media supplemented with 2 μg/ml
puromycin, 50 μg/ml hygromycin B or 500 μg/ml G418,
as appropriate. Viral particles were produced by calcium
phosphate transfection of 293 T cells [20]. Infectionswere performed at a multiplicity of 10 infectious units
per cell based on the MCF7 titer. The final 4G-shp53-
PI3K cells were uniformly positive for CFP and GFP,
which are carried by the BMI1 and shp53 vectors, respect-
ively, but showed heterogeneous staining for tdTomato be-
cause the tdTomato vector was added last, not selected
with an antibiotic and conferred no growth advantage on
the cells. For proliferation assays, cells were treated with 2
nM 17β-estradiol or 1 μM fulvestrant and counted at each
time point with a Coulter counter (Beckman Coulter, Brea,
CA, USA). To test for significant differences between the
growth curves in Figure 4B and Figure 10C, the slopes
were compared after linear regression on logged data with
the lm (linear model) function in R, with a correction in
Figure 4B for performing three tests.
Xenografts
The study was performed in accordance with European
Community Standards of Care and Use of Laboratory
Animals under level 2 containment at the University of
Bordeaux. Approval was granted for the animal experi-
ments by the Comite d’Ethique pour l’Experimentation
Animal (CEEA50) Ethics Committee, Bordeaux (project
number 5012034-A). For xenografts, 100,000 BPECs and
100,000 p53−/− mouse embryo fibroblasts irradiated with
30 Gy were mixed with 10% growth factor–reduced
Matrigel (BD Biosciences) and injected into 6-week-old
female NSG mice (nonobese diabetic, severe combined
immunodeficiency, interleukin 2 receptor gamma chain–
null, strain number 005557; The Jackson Laboratory, Bar
Harbor, ME, USA). The injection volumes were 100 μl
for subcutaneous injections and 10 μl for intraductal in-
jections [10]. Tumor size after subcutaneous injection
was measured with a PhotonIMAGER (Biospace, Paris,
France) and scaled to the size at the first time point in
each tumor group. To identify significant differences, t
tests were performed in R on logged data with a correc-
tion for performing five tests in Figure 6A and ten tests
in Additional file 2: Figure S2E and S2F. To measure
tumor size after intraductal injection, the glands were re-
moved at the end of the experiment and scanned as a
single group with the PhotonIMAGER.
Results
A new genetically defined human adenocarcinoma model
WIT medium was developed to prevent squamous meta-
plasia of genetically defined mammary tumors [2]. When
we grew reduction mammoplasty cells in WIT medium,
transformed them with TERT, BMI1, ESR1 and MYC,
and injected them subcutaneously into immunodeficient
mice, they formed mixed tumors that rapidly became
entirely squamous with the appearance of stratification
and keratin pearls. Figure 1B to 1E show the morph-
ology of the tumors. EGFR family members show
Figure 2 Epidermal growth factor receptor family gene expression in normal and tumor cells. (A) Illumina gene expression data from
normal human reduction mammoplasty cells LP, Luminal progenitor; MaSC, Mammary stem cell; ML, Mature luminal. Error bars represent
standard error of the mean. n = 3; †P < 0.01; *P < 0.05; the P-values are for comparisons of ML with the other groups. (B and C) Affymetrix gene
expression data for large operable or locally advanced breast cancer. The scatterplot in (B) shows how the tumors were classified into luminal
(ER+FOXA1+, 43 samples), molecular apocrine (ER−/FOXA1+, 49 samples) and basal-like (ER−/FOXA1−, 69 samples). The plots in (C) show the
expression profiles of EGFR family members in each tumor class. The distributions are strikingly bimodal (see text for details). The maximum
density for each distribution is scaled to 1 to facilitate comparison of the different tumor classes.
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cell subsets: EGFR expression is significantly lower in
mature luminal cells than in other subsets; ERBB3 ex-
pression is significantly lower in stem cells than in ma-
ture luminal cells; and luminal progenitors have an
intermediate phenotype (Figure 2A) [14,21]. EGFR family
members show strikingly bimodal patterns of expressionin human breast tumors: EGFR is higher in basal-like
and molecular apocrine tumors; ERBB2 is higher in mo-
lecular apocrine tumors; ERBB3 is higher in luminal
and molecular apocrine tumors; and ERBB4 is higher in
luminal tumors (Figure 2B, and 2C) [15,16,18]. On the
basis of these observations, histopathological data showing
EGFR expression by myoepithelial cells, keratinocytes and
Figure 3 Comparison of WIT medium containing EGF to WIT medium containing amphiregulin and neuregulin. Human mammary
epithelial cells were infected with vectors expressing TERT, BMI1, CCND1 and MYC. (A) Western blots showing that the transgenes are expressed.
The cells in medium containing amphiregulin and neuregulin (svWIT) have luminal characteristics. The cells in medium containing EGF (pWIT)
have stronger phosphorylation of EGFR. (B) Photomicrographs showing that cells in pWIT are a mixture of spindle shaped and rounder cells,
whereas cells in svWIT have a more uniform cobblestone appearance. Scale bars 250 μm. (C) Flow cytometry shows that cells in svWIT have a
putative luminal progenitor phenotype (CD49+/EPCAM+) whereas cells in pWIT are a mixture of putative luminal progenitors and myoepithelial
cells. The quadrants were defined by the isotype controls.
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motes expansion of the myoepithelial layer in short-
term organoid cultures [3], we reasoned that it might be
possible to reduce squamous metaplasia in engineered
tumor models by decreasing the activation of EGFR and
increasing that of ERBB3 and ERBB4. To test this hypoth-
esis, we grew normal reduction mammoplasty cells in
WIT medium containing either EGF (pWIT medium) or
amphiregulin (AREG) plus neuregulin (NRG1) (svWIT
medium). Parallel cultures in the two media were in-
fected first with TERT and BMI1 viruses and then super-
infected with CCND1 and MYC viruses to produce 4G
cells. Expression of the transgenes was confirmed by
Western blotting (Figure 3A and Additional file 1: Fig-
ure S1A). Cells grown in pWIT formed loose colonies of
spindle-shaped cells mixed with larger cells, whereas cells
in svWIT formed tighter colonies of round cells that
were more uniform in appearance (Figure 3B). Flowcytometry showed that the svWIT culture was homoge-
neous, with a single population high in EPCAM expres-
sion, low in CD10 expression and intermediate in
CD49f expression (Figure 3C). The cells in pWIT con-
tained two populations, one CD49f−/CD10+/EPCAM−
and the other CD49f+/CD10−/EPCAM+. The CD10+
population in pWIT could correspond to myoepithelial
cells. The EPCAM+ cells in both media are presumably
luminal cells. The EPCAM level is higher in svWIT than
pWIT, suggesting that the cells are more differentiated
in svWIT. Western blotting showed that the switch
from EGF to amphiregulin and neuregulin in svWIT de-
creased the level of EGFR receptor tail phosphorylation,
despite an increase in the amount of the protein
(Figure 3A), consistent with weaker activation of EGFR
and decreased receptor turnover. Western blotting of
the cells in pWIT showed that they express keratin 14
and ΔN-p63α strongly, confirming the suggestion arising
Figure 4 Silencing of p53 and activation of phosphatidylinositol 3-kinase in 4G cells. (A) Western blots showing that the shp53 vector
silences p53 expression and the PIK3CA vector increases phosphatidylinositol 3-kinase (PI3K) expression and Akt phosphorylation on T308.
(B) Growth curves comparing parental 4G cells with cells infected with the shp53 and PIK3CA vectors. Error bars represent standard error of the
mean. †P < 0.001; *P < 0.05; n = 5 biological replicates.
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populations in pWIT is myoepithelial or squamous.
The cells in svWIT expressed luminal markers (AGR2,
ERBB3 and keratin 18) (Figure 3A), as well as ERα
and ELF5 (Figure 3A), but not FOXA1 or GATA3
(Additional file 1: Figure S1B). ER, FOXA1 and GATA3
are markers for mature hormone-sensing cells, whereasFigure 5 Genomic profiles at different stages in the transformation p
cells infected with the PIK3CA vector show no copy number changes. Silen
changes on chromosomes 3 and 5 which do not progress after introductio
and 4G-shp53-PIK3CA cells is caused by four exonic probes in the PIK3CA loELF5 is a marker for the secretory lineage [24]. Coex-
pression of ER and ELF5, as seen in the cells grown in
svWIT medium, has been proposed to mark luminal
progenitors that have not yet committed to one lineage
[24]. We conclude that a shift in the balance of EGFR
family signaling in favor of ERBB3 selects for cells
that share some features with luminal progenitorsrotocol. Comparative genomic hybridization plots of 4G cells and 4G
cing of p53 in the 4G cells leads to loss of chromosome X and minor
n of the PIK3CA vector. The spike on chromosome 3q in 4G-PIK3CA
cus. There were no additional changes after passage in mice.
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cells.
Tumor formation by cells grown in svWIT medium
It was not possible to compare the phenotype of tumors
formed by 4G cells grown in the two media, because the
cells are not tumorigenic. To transform them fully, they
were infected with lentiviruses expressing PIK3CA-
H1047R and a short-hairpin RNA targeting TP53
(shp53). Western blotting showed that the shp53 vector
reduced the amount of p53 (Figure 4A). Cells infected
with the PIK3CA vector showed increased expression of
PI3K and increased phosphorylation of AKT on T308,
indicating that PDK1 was activated by PI3K (Figure 4A).
Growth curves showed that the shp53 and PIK3CA vec-
tors significantly increased the growth rate (Figure 4B).
As expected for genetically defined models of this type,
comparative genomic hybridization (CGH) profiles were
completely flat until p53 was silenced, but even cells
containing all six vectors had only minor changes (loss
of 3p21, gain of 5p14, loss of X) (Figure 5). Interestingly,
the breakpoint on 3p21 truncates PBRM1 (BAF180), a
known breast cancer tumor suppressor gene [25]. To de-
termine whether the cells were tumorigenic in vivo, they
were injected subcutaneously into immunodeficient
mice. Only the cells transduced with both the shp53 and
the PIK3CA vectors could form progressively growing
tumors (Figure 6A; the images of mice show how the
data were collected, and the graph shows fluorescence
normalized to the value one week after injection). Histo-
logical examination showed that the tumors were grade
3 adenocarcinomas (Figure 6B). The tumor cells stained
strongly with anti-GFP antibody and with human-
specific antibodies against keratins 7 and 19, confirming
that they were carcinoma cells [26] derived from the
injected human epithelial cells. Cells in contact with the
mouse stroma expressed p63 and keratin 14, suggesting
that they might be trying to form a myoepithelial bound-
ary layer (Figure 6B; the stroma is marked by an asterisk).
Cells in the main tumor mass expressed keratins 5/6 and
8/18. The overall pattern of keratin staining indicates that
the tumors were adenocarcinomas rather than squamous
carcinomas, but the presence of scattered p63-positive
cells and the induction of myoepithelial genes at
boundaries with mouse stroma suggest that the cells
may retain some common progenitor features. Import-
antly, the tumor cells were positive for ERα and Ki67
but negative for PGR (Figure 6B). The experiment was
repeated with two other mammoplasties (XS03 and
XS05), and expression of TERT, BMI1, MYC and CCND1
and activation of PI3K were confirmed by Western blot-
ting (Additional file 2: Figures S2A and S2B). Flow cytom-
etry showed the presence of a single EPCAM+ luminal
population (Additional file 2: Figures S2C and S2D).Subcutaneous xenografts only formed tumors following
introduction of the PIK3CA-H1047R vector (Additional
file 2: Figures S2E and S2F). We conclude that cells trans-
formed in medium containing amphiregulin and neuregu-
lin form luminal B mammary adenocarcinomas with
squamous metaplasia of cells in contact with the mouse
stroma.
Orthotopic tumor formation
Behbod and colleagues recently described a new ap-
proach to modeling DCIS by injecting cells through the
nipple directly into the mouse mammary ductal tree
[10]. To test whether exposure to this more physio-
logical environment would correct the transformed
phenotype of the 4G-shp53-PIK3CA cells, we mixed
them with irradiated mouse fibroblasts and laminin-rich
extracellular matrix (Matrigel) and injected the mixture
into the ducts. Fibroblasts and Matrigel were used to
promote the survival of the epithelial cells in the peri-
operative period, but we have not formally tested
whether they increase the rate of engraftment. In con-
trast to the Kuperwasser approach [27], the fibroblasts
were murine in origin and injected into the ducts, not
into the stroma. Six-week-old mice were injected be-
cause the majority of the primary ductal tree is present,
providing a large surface area for the human cells to
colonize, but the ducts are still growing and forming side
branches at this age, so the cells can potentially be incor-
porated into ducts as they are laid down.
Three weeks after injection, mice were killed and their
mammary glands were harvested for examination by
stereomicroscopy (Figure 7A). Clusters of fluorescent
cells were scattered throughout the injected glands.
At higher magnification, the main ducts and side
branches are clearly visible (Figure 7B). The injected
cells expressed red, blue and green fluorescent proteins,
but the strength of the red signal was variable in different
clones because the number of copies of the tdTomato pro-
virus varied between cells. Clusters of yellow cells alternate
with clusters of green cells in the right panel in Figure 7B,
indicating that different ratios of red and green vector
were present. We can infer that hundreds of cells success-
fully seeded independent tumor foci throughout the gland.
The hematoxylin and eosin (H&E) staining showed that
the mammary ducts were filled with cells resembling the
pattern seen in DCIS (Figure 7C). Immunohistochemistry
(IHC) for GFP confirmed that the tumor cells were de-
rived from the injected human cells. IHC for p63 and
SMA showed that the myoepithelial layer was present at
this stage (3 weeks after injection) (Figure 7C), indicating
that the tumor was a DCIS, but there were fewer myoe-
pithelial cells than in normal murine ducts (Figure 8). As
expected, the myoepithelial cells did not stain for GFP, in-
dicating that they were murine in origin (Figure 8: red
Figure 6 Subcutaneous tumor formation requires activation of phosphatidylinositol 3-kinase. (A) Red fluorescence was used to measure
subcutaneous tumor growth. Fluorescence in the circled region ("ODD") in photons per second per square centimeter per steradian was
normalized to the starting value one week after injection. n = 6; *, p < 0.05. (B) Histopathological (H&E stain) and immunohistochemical analyses
show that the tumor is an ERα+, Ki67+ adenocarcinoma. The asterisks mark an island of mouse stroma surrounded by human tumor cells. The
antibody against the progesterone receptor (PGR) gives a non-specific cytoplasmic stain in the stroma. Scale bars = 100 μm.
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tion of cells from the other mammoplasties also produced
ERα+DCIS (Additional file 2: Figure S2G). The tumor
cells were all positive for keratins 7, 8/18 and 19; most
were weakly positive for keratins 5/6; a few were positive for
keratin 14 (Figure 7C). This mixed luminal/basal pattern
has been reported to occur in one-fourth of primaryoperable breast tumors [28]. Interestingly, the cells were
positive for ERα and Ki67 but negative for PGR (Figure 7C;
the PGR stain is negative relative to control cells in the
same section).
Six weeks after injection, stereomicroscopy showed di-
lated ducts packed with fluorescent cells. There was
again variable red staining, indicating that multiple
Figure 7 Ductal carcinoma in situ formation 3 weeks after intraductal injection of 4G-shp53-PI3K tumor cells. (A) Composite image
showing human cells expressing cyan fluorescent protein scattered throughout the gland. (B) Enlarged images from A. The right panel shows
alternating clusters of yellow and green cells. (C) Hematoxylin and eosin and immunohistochemical stains showing estrogen receptor α–positive
(ERα+) and Ki67+ ductal carcinoma in situ (DCIS). The progesterone receptor (PGR) staining is negative in the tumor cell nuclei relative to controls
on the slide. GFP, Green fluorescent protein; K, Keratins; SMA, Smooth muscle actin. Scale bars = 1 mm (A and B) and 100 μm (C).
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Figure 8 The myoepithelial layer is murine in humanized
glands. Ducts humanized with 4G-shp53 cells were costained for
p63 (red), GFP (green) and DNA (DAPI, blue) (n = 3). All injected
human cells express GFP strongly. Green arrow, human luminal cells
in a humanized duct; red arrow, murine myoepithelial cells in a
murine duct. Scale bars 50 μm.
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neous staining, suggesting that individual clones had
expanded to fill those regions (Figure 9A). Eight
weeks after injection, the tumor had spread to fill large
contiguous parts of the ductal tree (Figure 9B). H&E
staining showed that the tumor had broken out of the
ducts and started to invade the mammary fat (Figure 9C).
Keratin 19 and GFP staining confirmed that the tumor
cells were derived from the injected human cells. The
tumor cells still expressed ERα, but the intensity of keratin
8/18 staining became weaker and that of keratin 14 stron-
ger as the cells migrated from the ducts into the stroma.
This was accompanied by histological features of early
squamous differentiation (pink cytoplasmic staining,
marked by arrows in Figure 9C, without stratification or
keratin pearls). We conclude that loss of environmental
cues when the tumor breaks free from the ducts allows the
cells to evolve toward a more adenosquamous phenotype,
although the squamous differentiation is much less pro-
nounced than in our previous model [12].
Because the tumors are potentially a model for high-
grade, ERα-positive breast cancer, they were tested for
estrogen dependence. Western blotting showed that
in vitro treatment with fulvestrant reduced the level of
ERα (Figure 10A), but the growth rate was unaffected
(Figure 10B and 10C). The cells were xenografted intra-
ductally into mice and allowed to form tumors for
3 weeks, after which the mice received weekly injectionsof fulvestrant for 5 weeks. IHC showed that the level of
ERα was lower in the tumors that received fulvestrant
than in the vehicle-treated controls (Figure 10D), con-
firming that the drug had reached its target in vivo. To
quantify the response, tumors were allowed to form in the
mice for 3 weeks, treatment was given for 3 weeks, the
injected mammary glands were excised and total tdTo-
mato fluorescence was measured (Figure 10E). There was
no significant difference between the treated and control
groups (Figure 10F). The lack of response in vitro and
in vivo mimics the resistance of human luminal B tumors
to endocrine therapy in patients with breast cancer.
Humanization of the mouse mammary gland
The Weinberg laboratory has shown that “humanization”
of the mouse mammary gland by human fibroblasts pro-
motes engraftment of human mammary epithelial cells
[27]. The epithelial cells form duct-like structures, but
they do not ramify to fill the gland with a normal ductal
tree, possibly because it is difficult to distribute human fi-
broblasts evenly throughout the fat pad. The logic behind
this approach is that subtle differences in signaling
proteins create a species barrier that prevents human
myoepithelial cells from communicating properly with
mouse fibroblasts. We reasoned that human luminal
cells might be able to communicate effectively with
mouse myoepithelial cells; therefore, we tried to use
the mouse myoepithelial layer as a scaffold upon which
to build a human luminal epithelium. We initially
attempted to humanize the ducts of NSG mice by
intraductal injection of reduction mammoplasty cells
immortalized by TERT and BMI1 (“2G” cells), but the
cells were rapidly lost. To give the human cells a pro-
liferative advantage over the resident murine luminal
cells, we tested 4G-shp53 cells, which, as we described
above, are nontumorigenic (Figure 6A). Three weeks
after intraductal injection, there was much less fluores-
cence in the injected glands than after injection of
their PIK3CA-transformed counterparts (Figure 11A).
Histological examination showed that small clumps of
human cells had penetrated the mouse luminal layer
and had attached to the underlying murine myoepithe-
lial layer (Figure 11B). By 6 weeks, large segments of
the mammary ductal tree were fluorescent, indicating
that viable human cells had engrafted and increased in
number. The presence of alternating yellow and green
regions showed that the grafts were derived from mul-
tiple different clones (Figure 12A). IHC for GFP con-
firmed that extensive regions of the ductal tree
contained human cells (Figure 12B). Histologically, the
human cells were slightly larger than the murine lu-
minal cells, but there was no evidence of the premalig-
nant changes of the sort usually observed in flat
epithelial atypia or atypical ductal hyperplasia [29].
Figure 9 Invasive tumor formation 6 and 8 weeks after intraductal injection of 4G-shp53-PI3K tumor cells. (A) Mammary ducts dilated by
human tumor cells at 6 weeks. (B) Diffuse blue masses 8 weeks after intraductal injection caused by tumor cells invading the stroma. (C) Mixed DCIS
and invasive tumor at 8 weeks. Hematoxylin and eosin and immunohistochemical stains show increased keratin 14 (K14) staining as cells migrate from
the ducts into the stroma. Early squamous changes are marked by arrows. There are small differences in the structures in the serial sections in
(C) because the structures gradually change as the sectioning proceeds through the paraffin block. ER, Estrogen receptor; GFP, Green fluorescent
protein; Scale bars = 1 mm (A), 2 mm (B) and 100 μm (C), respectively.
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but the myoepithelial layer was murine, as shown by the
absence of cells positive for both p63 and GFP in double-
labeled sections (Figure 13). The myoepithelial layer was
intact, as judged by staining for SMA, but the number ofmyoepithelial cells was lower than in contiguous regions
with murine luminal cells. All of the human cells
expressed ERα, and many expressed Ki67, but they did not
express PGR, FOXA1 or GATA3 (Figure 12C and 12D),
consistent with their in vitro profile. To test whether the
Figure 10 Tumor growth is not inhibited by fulvestrant. (A) Western blot showing that treatment of 4G-shp53-PI3K tumor cells with 1 μM
fulvestrant reduces the level of ERα. Fulvestrant has no effect on proliferation of the cells measured by crystal violet staining (B) or growth
curves (C). Fulvestrant treatment was started at the arrow (day 3). n= 3; DMSO, Dimethyl sulfoxide; NS, not significant. Scale bars = 1 cm. (D) 4G-shp53-PI3K
cells were injected into the ducts, allowed to form tumors for 3 weeks and then treated with fulvestrant or vehicle for 5 weeks. Representative
immunohistochemical images show a marked reduction in ERα levels in treated tumors. Each image is derived from a separate animal (n = 6 for
control, n = 7 for fulvestrant). The slides were all processed together. Scale bars = 50 μm. (E) and (F) 4G-shp53-PI3K cells were injected into the
ducts, allowed to form tumors for 3 weeks and then treated with fulvestrant or vehicle for 3 weeks. PhotonIMAGER scans (E) of excised mammary
glands after treatment with fulvestrant or vehicle (control) show how the response was quantified. The scanner counts fluorescence emitted by
tdTomato. Graph in F shows quantitative data from the glands shown in E (n = 8 for control, n = 9 for fulvestrant).
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injected into the mammary ducts of two mice and allowed
to replace the luminal layer of the ducts. The mice were
then mated and sacrificed on day 1 of lactation, 14 weeks
after injection of the human cells. The human cells were
restricted to the ducts and did not form alveoli, althoughsome human cells in the ducts did undergo secretory dif-
ferentiation (Figure 14: open arrowheads show murine al-
veoli; filled arrowheads show a nonsecretory humanized
duct; and arrows show casein-expressing cells in a hu-
manized duct). Taken together, the data suggest that
the cells immortalized by the TERT, BMI1, CCND1,
Figure 11 Foci of engrafted human cells 3 weeks after
intraductal injection of 4G-shp53 cells. (A) Stereomicrograph
showing isolated foci of human cells. The images cover a single
gland with a small overlap in the middle. Scale bar = 1 mm.
(B) Attachment of 4G-shp53 cells to the duct wall 3 weeks after
intraductal injection. Left panels, hematoxylin and eosin (H&E)
staining. Right panels, matched sections showing green fluorescent
protein (GFP) staining to identify the human cells. The clumps of human
cells correspond to the scattered foci of fluorescent cells visualized by
stereomicroscopy in (A). Scale bar = 100 μm. n= 2 mice.
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hormone-sensing or secretory cells trapped at the luminal
progenitor stage.Discussion
We have shown that genetically defined human mam-
mary epithelial cells expressing multiple oncogenes can
form a morphologically normal luminal layer in the
mouse mammary gland and that expression of a single
additional activated oncogene, PIK3CA-H1047R, is suffi-
cient to convert them into invasive ERα+ adenocarcin-
oma cells. Two factors were probably critical to the
success of the approach: the use of oncogenes commonly
mutated or amplified in ERα+ breast cancer and the useof culture medium favoring ERBB3 over EGFR signaling
to prevent squamous metaplasia in vitro.
Previous attempts to make breast cancer models by
transformation of normal human mammary epithelial
cells typically led to the formation of overtly squamous
tumors that are unrepresentative of breast cancers seen
in human patients. Several arguments implicate EGFR
signaling in squamous metaplasia. First, EGFR is prom-
inently expressed in the skin [22]. Second, the myoe-
pithelial layer proliferates at the expense of the luminal
layer in short-term organoid culture in media containing
commonly used levels of EGF [3]. Third, deletion of
Erbb3 in mice leads to loss of the luminal layer and ex-
pansion of the basal/myoepithelial layer [30]. Fourth,
EGFR is preferentially expressed by stem cells and basal-
like tumors, whereas ERBB3 is expressed by mature lu-
minal cells and luminal tumors; luminal progenitors ex-
press both receptors, presumably because of their
intermediate status (Figure 2 and [21,30]). To attenuate
EGFR signaling, we replaced EGF in the culture medium
with amphiregulin, which is 100-fold less active on
EGFR [3], and added neuregulin, which activates ERBB3
and ERBB4 [31]. The WIT medium we used was devel-
oped specifically to promote the growth of luminal cells
[2], but in the conditions we used, cell lines established
in EGF-containing WIT medium underwent squamous
metaplasia. Furthermore, our cell lines established in
amphiregulin/neuregulin medium grow poorly if trans-
ferred back into EGF medium, suggesting that the
amphiregulin/neuregulin combination not only prevents
overgrowth of a confused myoepithelial population but
also favors the growth of luminal cells. That said, we
fully agree with Ince et al. [2] that WIT medium favors
the growth of luminal cells. We suspect that the differ-
ences between our results and theirs reflect subtle differ-
ences in the formulation of the medium, the origin of
the cells or the choice of transforming genes. Whatever
the reason, our results indicate that replacement of EGF
with amphiregulin and neuregulin is a simple modifica-
tion that turns WIT into an even more robust luminaliz-
ing medium.
Transgenic mouse models frequently produce tumors
with histological features rarely seen in human breast
cancer patients. The striking feature of PI3K-induced
mouse models is the extent to which they express ERα,
despite their unpromising histology [32]. This points to
a role for PI3K in the regulation of ERα expression, but
the cells in our model already formed ERα+ xenografts
before infection with the PIK3CA vector. The Kuperwas-
ser group has described a model based on CCND1,
PI3K, KRAS and TP53 that produces ERα+ tumors [4,5].
CCND1 is a strong candidate for driving ERα+ tumor
formation in both our models because it is commonly
amplified in ERα+ tumors and activates ERα in the
Figure 12 (See legend on next page.)
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Figure 12 Replacement of the murine luminal layer 6 weeks after intraductal injection of 4G-shp53 cells. (A) Stereomicrograph showing
spread of human cells within the ducts. Alternating yellow and green areas in the right panel demonstrate independent engraftment of multiple
clones. (B and C) Histopathology (hematoxylin and eosin stain) and immunohistochemistry show that the human cells have replaced the murine
luminal layer with morphologically normal human cells. The human cells are larger, as seen at junctions between murine and human luminal
cells. Green fluorescent protein (GFP), keratin 7 (K7) and keratin 19 (K19) staining specifically label the human cells. The cells are estrogen receptor
α–positive (ERα+), progesterone receptor–negative (PGR−), Ki67+ luminal cells. Smooth muscle actin (SMA) staining shows that the myoepithelial
layer is intact. (D) GATA binding protein 3 transcription factor (GATA3) and Forkhead box A1 transcription factor (FOXA1) are positive in murine
ducts (marked by arrows), but negative in humanized ducts (marked by an arrowhead). Scale bars = 1 mm (A), 100 μm (B), 50 μm (C) and
200 μm (D), respectively.
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ments, the rationale for using CCND1, PI3K-H1047R,
MYC, TERT, BMI1 and sh-p53 was based on genomic
data in luminal breast cancer and on past experience
with mammary transformation protocols. According to
the Cancer Genome Atlas Network, PIK3CA mutations
are seen in 45% of luminal A tumors and 29% of luminal
B tumors, and TP53 mutations are seen in 29% of
luminal B tumors [35]. MYC was included in the trans-
formation cocktail because Elenbaas et al. reported that
the endogenous MYC gene would amplify spontaneously
if MYC was not supplied exogenously in their transform-
ation protocol [36], and TERT was included to prevent
telomere erosion [1]. BMI1 is preferentially expressed by
luminal tumors [12,37] and cooperates well with MYC
[38], but it was included mainly to prevent unwanted
differentiation or genomic instability at early times after
the cells were put into culture [12,39]. It is possible thatFigure 13 The myoepithelial layer is murine in humanized
glands. Ducts humanized with 4G-shp53 cells were costained
for p63 (red), green fluorescent protein (GFP, green) and DNA
(4′,6-diamidino-2-phenylindole (DAPI), blue) (n = 3). All injected
human cells express GFP strongly. Green arrow, human luminal
cells in a humanized duct; red arrow, murine myoepithelial cells
in a murine duct. Scale bars = 50 μm.in the new medium it may not be necessary. BMI1 pre-
vents activation of the p53 and Rb pathways [40], but
the fact that silencing of p53 by RNA interference is re-
quired for full transformation in our model indicates
that BMI1 is having at best a partial effect. We suspect
this is because BMI1 is expressed at a low level by our
lentiviral vector. After silencing of p53, the cells from
the XS11 mammoplasty acquired a deletion on 3p21
starting within PBRM1, the gene encoding the BAF180
subunit of the polybromo- and BRG1-associated ATP-
dependent chromatin-remodeling complex [41]. Trun-
cating mutations, as seen here, have previously been de-
scribed in breast cancer, where they reduce p21
induction by transforming growth factor β and p53 [25].
We have not performed CGH on multiple independently
derived cell lines, so we cannot say whether this change
is absolutely required for transformation with CCND1,
PI3K-H1047R, MYC, TERT, BMI1 and sh-p53, but it
seems unlikely. Indeed, the more striking feature is how
flat the profiles are after transformation with defined on-
cogenes, something we also saw in our previous ER+
model [12].
Despite robust ERα expression, there was no response
to fulvestrant. CCND1 and mutant PIK3CA can confer
resistance to endocrine therapy in cell lines, but the
relationship between PIK3CA mutation and the re-
sponse to endocrine therapy is hotly debated [42].
Paradoxically, PIK3CA mutations are associated with
a gene signature of low mammalian target of rapa-
mycin complex 1 (mTORC1) signaling and better
outcomes in ERα+ breast cancer [43]. It will be inter-
esting to see whether the genetically defined ERα+
PIK3CA-mutant model we have developed can shed
fresh light on this problem.
Genomic studies indicate that DCIS has a mutation
profile similar to that seen in invasive cancer [44], and
molecular clock studies indicate that breast tumors
undergo little clonal expansion or genomic rearrange-
ment until the last driver mutation is acquired [45].
Taken together, these results push the timeline for acqui-
sition of oncogenic mutations far before the formation
of DCIS. Our data following intraductal injection of 4G-
shp53 cells show that cells with all but the last driver
mutation can form a morphologically normal luminal
Figure 14 4G-shp53 cells can undergo secretory differentiation
but do not form normal alveoli. Mice with human cells engrafted
in the ducts were sacrificed on day 1 of lactation (n = 2). Hematoxylin
and eosin (H&E) stain and immunohistochemistry for green fluorescent
protein (GFP) show that human cells are present in the ducts but do
not spread into the lactating alveoli. Immunohistochemistry for casein
shows that some of the human cells in the ducts have undergone
secretory differentiation. The structures in the middle of the image are
mouse alveoli (open arrowheads). They do not stain for casein, because
the antibody is human-specific. The structure on the right is a
humanized duct containing cells that do not express casein
(closed arrowheads). The structure on the left is a humanized duct
containing cells that do express casein (arrows). Scale bars 200 μm.
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over the murine luminal cells they replace, but, apart
from being bigger than murine luminal cells, they are
normal in appearance. They do not survive after sub-
cutaneous injection, indicating that mammary ducts
provide a more welcoming environment than skin. The
microenvironment of the duct seems to promote glan-
dular differentiation: the transformed cells were pre-
dominantly keratin 18–positive/keratin 14-negative
while confined to the ducts, but keratin 14 expression
increased when these cells migrated into the stroma. A
possible interpretation of this is that the murine
stroma is programmed to release EGF in amounts ap-
propriate for murine progenitors but excessive for hu-
man progenitors [3]. Alternatively, the fact that
occasional human cells bordering the necrotic core of
the largest DCIS lesions expressed p63 suggests that
squamous differentiation may be a cell-autonomous ef-
fect that normal myoepithelial cells prevent through
release of a diffusible factor.
We see humanization of the luminal layer in the
mouse ducts after intraductal injection as a form of tis-
sue engineering in which the murine myoepithelial layer
serves as a scaffold on which to build a human luminal
layer. The failure of human cells to form a normal mam-
mary ductal tree after xenografting into the mouse
mammary fat pad is normally explained by the existence
of a species barrier between human myoepithelial cells
and mouse stromal cells. The Weinberg group has
shown that this barrier can be partially overcome by in-
filtration of the mouse stroma with human fibroblasts
[27]. Our results indicate that it may be better to retain
the mouse myoepithelial layer and replace only the lu-
minal layer with human cells. To do this, we used an
intraductal xenografting approach developed by Behbod
and colleagues, who showed that the approach is strik-
ingly effective for growth of primary human DCIS cells
in the mouse [10]. The DCIS histology in the mouse
faithfully recapitulated the histology of the human sam-
ple from which it was derived and included regions
where hyperplastic human cells formed single- and
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suggest that intraductal grafting is a major advance over
previous approaches to model human breast cancer biol-
ogy in the mouse. We were not able to replace the mur-
ine luminal layer with unmodified human cells. Instead,
we started with fully transformed cells and removed one
oncogene, PIK3CA. Although the 4G-shp53 cells were
able to form a morphologically normal luminal layer in
the ducts, they were clearly not functionally normal, be-
cause they could not form normal alveolar structures
in lactating mice. It will be interesting to test cells
expressing even fewer oncogenes to determine the
point at which human cells lose their competitive ad-
vantage over mouse cells, in order to see whether
they can fully humanize the gland and produce func-
tioning alveoli.
A weakness of mouse transgenic models in general is
the strong tendency for tumor histology not to resemble
that of human breast cancer. One reason may be a fun-
damental difference in the cell of origin of murine and
human mammary tumors. Recent work carried out in
the Blanpain laboratory has identified a long-lived lu-
minal stem cell [6] whose human homolog is a strong
candidate for the cell of origin of luminal, molecular
apocrine and basal-like human breast cancers. The
ERα+, ELF5+ cell in our cultures could be the preneo-
plastic counterpart of this cell. Recent work done in the
Ormandy laboratory indicates that ERα and ELF5 cross-
inhibit one another in luminal progenitors, with defini-
tive hormone-sensing or secretory lineage differentiation
ensuing when one factor triumphs over the other [24].
This is perfectly consistent with the failure of our trans-
formed cells to respond to inhibition of ERα with fulves-
trant. Drawing parallels between normal lineages and
tumor cells is fraught with difficulty because tumor cells
inevitably fail many of the tests cell biologists use to
characterize normal cells, such as differentiation of pro-
genitors into mature, terminally differentiated cells.
Nevertheless, taken together, our data suggest that injec-
tion of genetically engineered human cells into the
mouse mammary ducts may provide a strategy to study
the differentiation of normal and malignant human
mammary epithelial cells in a more physiological context
than has hitherto been possible.Conclusion
We have shown that altering the balance of EGFR family
signaling in favor of ERBB3/ERBB4 prevents squamous
metaplasia of mammary epithelial cells in vitro, that hu-
man cells with multiple defined oncogenic changes can
replace the luminal cell layer in the mouse mammary
gland with a morphologically normal luminal layer of
human cells, and that addition of a single activatedoncogene, mutant PIK3CA, is sufficient to convert these
cells into invasive ERα+ adenocarcinoma cells.
Additional files
Additional file 1: Figure S1. Western blots showing expression of the
transgenes in 4G and parental cells (A) and lack of FOXA1 and GATA3
expression in 4G cells (B). MCF7 cells were used as a positive control for
the FOXA1 and GATA3 blots. p4 to p6, different passages of the 4G cells
in svWIT medium.
Additional file 2: Figure S2. Transformation in svWIT with different
mammoplasties (XS03 and XS05). Western blots showing expression of
the TERT, BMI1, MYC and CCND1 transgenes (A) and phosphorylation of
AKT on T308 induced by PI3K (B). Flow cytometry shows the formation
of single populations of EPCAM+ cells after transformation in XS05 (C) and
XS03 (D). The quadrants were defined by the isotype controls. 4G-shp53 cells
are unable to survive after subcutaneous xenografting. Only the cells
superinfected with the PIK3CA vector survive and form tumors in XS05
(E) and XS03 (F) (n = 5). (G) DCIS after intraductal injection of XS05
4G-shp53-PI3K cells (H&E staining and IHC for ERα Ki67, GFP, p63, SMA and
keratins). Scale bars, 100 μm.
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